Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.47 |
| ▸ | ELANE | P08246 | 9/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7590081 | 0.79 | PDE10A (0.58) | DHODHPDE10ATSHRMEN1KMT2A | |
| SCHEMBL3423936 | 0.79 | PDE10A (0.50) | DHODHPDE10ATSHRKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL9842693 | 0.78 | PDE10A (0.57) | DHODHPDE10ATSHRMEN1KMT2A | |
| SCHEMBL28129472 | 0.75 | PDE10A (0.50) | DHODHPDE10ATSHRMEN1KMT2A | |
| SCHEMBL3423212 | 0.72 | DHODH (0.47) | DHODHELANEPDE10ATSHRPARP1 | |
| SCHEMBL13433220 | 0.70 | MEN1 (0.56) | PDE10AKDM4EMEN1KMT2AKCNA3 | |
| SCHEMBL10258857 | 0.70 | PDE10A (0.54) | DHODHELANEPDE10ATSHRPARP1 | |
| SCHEMBL6782711 | 0.69 | DHODH (0.49) | DHODHELANEPDE10ATSHRPARP1 | |
| SCHEMBL618719 | 0.68 | HSD17B10 (0.53) | DHODHELANEPDE10APARP1KDM4E | |
| SCHEMBL8168011 | 0.68 | PDE10A (0.47) | DHODHPDE10ATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7695980-B2 | Chemiluminescent compounds and their use | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20060199833-A1 | Novel chemiluminescent compounds and their use | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1658495-A1 | NOVEL CHEMILUMINESCENT COMPOUNDS AND THEIR USE | Roche Diagnostics GmbH (DE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005015214-A1 | NOVEL CHEMILUMINESCENT COMPOUNDS AND THEIR USE | ROCHE DIAGNOSTICS GMBH (DE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199833-A1 | Novel chemiluminescent compounds and their use | LANCL1, LPO, HLCS | DHODH 1723/4885ELANE 78/4885PDE10A 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.